Novartis AG
NVSNYSEUSD
- Source valuation snapshot. Not a live recalculation.
- Latest filed annual earnings; price snapshot date unavailable. Not forward P/E.
- Diluted earnings per share from the latest filed annual.
- $163.26 Prior regular-session close from the quote source.
- $159.21–$160.62 Regular-session low and high so far today.
- 2.3M Regular-session shares traded · Nov 11, 4:00 PM ET.
- Not yet confirmed The company has not confirmed its next report date. Reported quarters are available in the chart’s Earnings view.
- $123.24–$170.46 52-week trading low and high returned by the quote source.
Understand the Business
Why the Stock Moved
Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.
The core investment thesis
Own NVS if Novartis converts steady high-margin branded-medicine sales plus rising operating cash flow into shareholder returns and disciplined R&D spending; the stock depends on the pipeline and protected franchises keeping competitors and biosimilars at bay.
NVS price history
Loading recent earnings…
Investment thesis
What must happen next
Sustained operating-margin expansion will be driven by sales mix (patented branded medicines and successful lifecycle management) and cost discipline, keeping operating income growing even as older SKUs decline.StrengtheningMateriality: High
operating_income increased from 7,946,000,000 USD (FY2022) to 17,644,000,000 USD (FY2025). If true, Novartis can convert sales into higher operating profit and cash, supporting buybacks/dividends and justifying a premium multiple; if false, margins and cash fall and the valuation compresses.
Watch: loss of exclusivity on a major biologic with rapid biosimilar uptake (e.g., a large competitor or multiple biosimilar entrants winning formulary access).
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
operating_income increased from 7,946,000,000 USD (FY2022) to 17,644,000,000 USD (FY2025).
Open source ↗Consistent, growing operating cash flow provides the capital engine to fund dividends, buybacks and targeted R&D/M&A without stretching the balance sheet.StrengtheningMateriality: High
operating_cash_flow rose from 14,236,000,000 USD (FY2022) to 19,144,000,000 USD (FY2025). Reliable free cash lets management return cash and invest in the pipeline while avoiding destructive dilution or leverage; a break forces dilution or cuts to returns.
Watch: large, unexpected M&A that consumes cash and increases leverage without clear return (an ill-timed transformative acquisition).
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
operating_cash_flow rose from 14,236,000,000 USD (FY2022) to 19,144,000,000 USD (FY2025).
Open source ↗Top-line and gross-profit growth will continue if late-stage assets successfully commercialize and achieve adoption; new launches are the principal growth lever.HoldingMateriality: Medium
gross_profit increased every year from 31,879,000,000 USD (FY2022) to 42,975,000,000 USD (FY2025), implying successful additions to the product mix. Successful launches provide organic growth and margin tailwinds; failed readouts or regulatory setbacks would remove the main path to sustained growth.
Watch: late-stage clinical trial failures or regulatory non-approvals for material assets.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
gross_profit increased every year from 31,879,000,000 USD (FY2022) to 42,975,000,000 USD (FY2025), implying successful additions to the product mix.
Open source ↗EPS growth will be sustained by operating-income expansion plus capital returns (buybacks) rather than financial engineering alone.HoldingMateriality: Medium
eps_diluted moved from 3.17 USD (FY2022) to 7.15 USD (FY2025), showing multi-year increase despite some volatility. EPS growth funded by core operating improvement is durable and supports valuation; EPS driven by one-offs or heavy dilution is not.
Watch: large, dilutive acquisitions or unexpected impairment/one-time charges that reduce GAAP EPS.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
eps_diluted moved from 3.17 USD (FY2022) to 7.15 USD (FY2025), showing multi-year increase despite some volatility.
Open source ↗A strong balance sheet (cash and equity) cushions the business against trial setbacks and lets Novartis continue R&D investment and selective bolt-ons to shore up growth.StrengtheningMateriality: Medium
cash and cash equivalents reported roughly 13,393,000,000 USD (FY2023) and ~11,435,000,000 USD (FY2025), indicating material liquidity. If true, management can sustain long-term investment through setbacks without forced asset sales or heavy dilution; if false, a single pipeline failure could force value-destructive decisions.
Watch: material cash burn from a failed large-scale program or a sizeable acquisition that removes the liquidity cushion.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
cash and cash equivalents reported roughly 13,393,000,000 USD (FY2023) and ~11,435,000,000 USD (FY2025), indicating material liquidity.
Open source ↗
Full investment case & evidence
Loading the original research archive…
Original research
Sustained operating-margin expansion will be driven by sales mix (patented branded medicines and successful lifecycle management) and cost discipline, keeping operating income growing even as older SKUs decline. If true, Novartis can convert sales into higher operating profit and cash, supporting buybacks/dividends and justifying a premium multiple; if false, margins and cash fall and the valuation compresses.
Consistent, growing operating cash flow provides the capital engine to fund dividends, buybacks and targeted R&D/M&A without stretching the balance sheet. Reliable free cash lets management return cash and invest in the pipeline while avoiding destructive dilution or leverage; a break forces dilution or cuts to returns.
Top-line and gross-profit growth will continue if late-stage assets successfully commercialize and achieve adoption; new launches are the principal growth lever. Successful launches provide organic growth and margin tailwinds; failed readouts or regulatory setbacks would remove the main path to sustained growth.
EPS growth will be sustained by operating-income expansion plus capital returns (buybacks) rather than financial engineering alone. EPS growth funded by core operating improvement is durable and supports valuation; EPS driven by one-offs or heavy dilution is not.
A strong balance sheet (cash and equity) cushions the business against trial setbacks and lets Novartis continue R&D investment and selective bolt-ons to shore up growth. If true, management can sustain long-term investment through setbacks without forced asset sales or heavy dilution; if false, a single pipeline failure could force value-destructive decisions.
All standing thesis claims
Original report summary
Novartis converts steady high-margin branded-medicine sales plus rising operating cash flow into shareholder returns and disciplined R&D spending; the stock depends on the pipeline and protected franchises keeping competitors and biosimilars at bay.
Bull case and bear case
Bull case and bear case for Novartis Ag
Where the evidence on Novartis Ag stands: Holding on the latest evidence (Oct 13, 2026). Of its 5 thesis points, 3 strengthening and 2 holding.
Bull case: what the evidence supports
Sustained operating-margin expansion will be driven by sales mix (patented branded medicines and successful lifecycle management) and cost discipline, keeping operating income growing even as older SKUs decline.
Consistent, growing operating cash flow provides the capital engine to fund dividends, buybacks and targeted R&D/M&A without stretching the balance sheet.
Top-line and gross-profit growth will continue if late-stage assets successfully commercialize and achieve adoption; new launches are the principal growth lever.
EPS growth will be sustained by operating-income expansion plus capital returns (buybacks) rather than financial engineering alone.
A strong balance sheet (cash and equity) cushions the business against trial setbacks and lets Novartis continue R&D investment and selective bolt-ons to shore up growth.
Bear case: what would count against it
loss of exclusivity on a major biologic with rapid biosimilar uptake (e.g., a large competitor or multiple biosimilar entrants winning formulary access).
large, unexpected M&A that consumes cash and increases leverage without clear return (an ill-timed transformative acquisition).
late-stage clinical trial failures or regulatory non-approvals for material assets.
Thesis-Break Engine
What has broken in Novartis Ag’s thesis
Each break OptimistFi flagged on Novartis Ag, dated — with what has historically followed the same kind of break across the market, not a forecast for Novartis Ag.
- Analyst downgradecondition set before this filing
Across all companies, this kind of break has happened 12,641 times before. Those stocks trailed comparable companies by a median of 1% over the next six months, and 33% of them trailed it by 10 points or more.
MARKET + FINANCIAL SNAPSHOT
The numbers behind the thesis
What Changed
- MixedForeign issuer material report (6-K).
Novartis Ag filed an SEC report on 2026-09-08: Foreign issuer material report (6-K). It is a dated development that tests the current thesis.
- MixedForeign issuer material report (6-K).
Novartis Ag filed an SEC report on 2026-09-04: Foreign issuer material report (6-K). It is a dated development that tests the current thesis.
- MixedForeign issuer material report (6-K).
Novartis Ag filed an SEC report on 2026-09-01: Foreign issuer material report (6-K). It is a dated development that tests the current thesis.
Risks / falsifiers
What could break the thesis
- loss of exclusivity on a major biologic with rapid biosimilar uptake (e.g., a large competitor or multiple biosimilar entrants winning formulary access).
- large, unexpected M&A that consumes cash and increases leverage without clear return (an ill-timed transformative acquisition).
- late-stage clinical trial failures or regulatory non-approvals for material assets.
- large, dilutive acquisitions or unexpected impairment/one-time charges that reduce GAAP EPS.
- material cash burn from a failed large-scale program or a sizeable acquisition that removes the liquidity cushion.
NVS news
Loading headlines…
Financial statements
NVS income statement
Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.
NVS: quick answers
- What is NVS's short interest?
- As of October 30, 2026, 4.5M NVS shares were sold short, down 19.2% from the count before. At the stock's average daily volume that is 1.9 days to cover. FINRA publishes the count twice a month. NVS short interest history
- Have members of Congress traded NVS?
- Reports made public in the last 90 days disclose 1 trade in NVS by 1 filer: 0 purchases and 1 sale. They are filed under the STOCK Act by members of Congress, the President and senior officials. Every disclosed NVS trade
- Which well-known investors own NVS?
- 2 of the 37 well-known funds tracked here reported NVS shares in their latest 13F filings. By share of the fund's portfolio: Glenview Capital Management, 0.3%; Maverick Capital, 0.0%. Fund portfolios
NVS in well-known investors’ portfolios
2 of 37 funds reported NVS shares in their latest 13F filing. A 13F shows quarter-end positions and arrives up to 45 days later.
| Fund | Of its portfolio | Value | Change | Quarter |
|---|---|---|---|---|
| Glenview Capital Management | 0.25% | $13.6M | New | Q2 2026 |
| Maverick Capital | 0.04% | $4.4M | +82.3% | Q2 2026 |